• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

化疗诱导的远端增强子驱动转录程序以维持卵巢癌的化疗耐药状态。

Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer.

机构信息

Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, Virginia.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

出版信息

Cancer Res. 2019 Sep 15;79(18):4599-4611. doi: 10.1158/0008-5472.CAN-19-0215. Epub 2019 Jul 29.

DOI:10.1158/0008-5472.CAN-19-0215
PMID:31358529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6744966/
Abstract

Chemoresistance is driven by unique regulatory networks in the genome that are distinct from those necessary for cancer development. Here, we investigate the contribution of enhancer elements to cisplatin resistance in ovarian cancers. Epigenome profiling of multiple cellular models of chemoresistance identified unique sets of distal enhancers, super-enhancers (SE), and their gene targets that coordinate and maintain the transcriptional program of the platinum-resistant state in ovarian cancer. Pharmacologic inhibition of distal enhancers through small-molecule epigenetic inhibitors suppressed the expression of their target genes and restored cisplatin sensitivity and . In addition to known drivers of chemoresistance, our findings identified SOX9 as a critical SE-regulated transcription factor that plays a critical role in acquiring and maintaining the chemoresistant state in ovarian cancer. The approach and findings presented here suggest that integrative analysis of epigenome and transcriptional programs could identify targetable key drivers of chemoresistance in cancers. SIGNIFICANCE: Integrative genome-wide epigenomic and transcriptomic analyses of platinum-sensitive and -resistant ovarian lines identify key distal regulatory regions and associated master regulator transcription factors that can be targeted by small-molecule epigenetic inhibitors.

摘要

化学耐药性是由基因组中独特的调控网络驱动的,这些网络与癌症发展所必需的网络不同。在这里,我们研究了增强子元件对卵巢癌顺铂耐药性的贡献。对多种化学耐药性细胞模型的表观基因组分析确定了独特的远端增强子、超级增强子 (SE) 及其基因靶标,这些靶标协调并维持卵巢癌中铂耐药状态的转录程序。通过小分子表观遗传抑制剂抑制远端增强子可抑制其靶基因的表达,并恢复顺铂敏感性。除了已知的化学耐药性驱动因素外,我们的研究结果还确定了 SOX9 作为关键 SE 调节转录因子,在卵巢癌获得和维持化学耐药状态中发挥关键作用。这里提出的方法和发现表明,整合分析表观基因组和转录组程序可以确定癌症中可靶向的化学耐药关键驱动因素。意义:对铂敏感和耐药卵巢系进行全基因组表观基因组和转录组综合分析,确定了关键的远端调控区域和相关的主调控转录因子,这些区域和转录因子可以被小分子表观遗传抑制剂靶向。

相似文献

1
Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer.化疗诱导的远端增强子驱动转录程序以维持卵巢癌的化疗耐药状态。
Cancer Res. 2019 Sep 15;79(18):4599-4611. doi: 10.1158/0008-5472.CAN-19-0215. Epub 2019 Jul 29.
2
Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.通过甲基化组和表达谱分析鉴定卵巢癌获得性顺铂耐药的候选 DNA 甲基化驱动因子。
Oncogene. 2012 Oct 18;31(42):4567-76. doi: 10.1038/onc.2011.611. Epub 2012 Jan 16.
3
Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.鉴定卵巢癌中与化疗耐药相关的新型缺氧标志物。
BMC Cancer. 2015 Jul 25;15:547. doi: 10.1186/s12885-015-1539-8.
4
MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.miR-139 通过调控 ATP7A/B 使卵巢癌细胞对顺铂为基础的化疗敏感。
Cancer Chemother Pharmacol. 2018 May;81(5):935-947. doi: 10.1007/s00280-018-3548-1. Epub 2018 Mar 28.
5
Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.卵巢癌中与铂类药物再敏感相关的基因组和表观基因组特征。
Cancer Res. 2018 Feb 1;78(3):631-644. doi: 10.1158/0008-5472.CAN-17-1492. Epub 2017 Dec 11.
6
The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.顺铂诱导的长链非编码 RNA PANDAR 通过调控 SFRS2 介导的 p53 磷酸化决定卵巢癌的化疗耐药性。
Cell Death Dis. 2018 Oct 30;9(11):1103. doi: 10.1038/s41419-018-1148-y.
7
Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.化疗敏感和耐药卵巢癌细胞中多重耐药 lncRNA 谱。
J Cell Physiol. 2018 Jun;233(6):5034-5043. doi: 10.1002/jcp.26369. Epub 2018 Jan 2.
8
DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through Overexpression in Cancer Cells.miR-7 的 DNA 甲基化是通过癌细胞过表达参与铂类药物反应的机制。
Theranostics. 2017 Sep 22;7(17):4118-4134. doi: 10.7150/thno.20112. eCollection 2017.
9
Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin.靶向高迁移率族蛋白 B3 使顺铂耐药卵巢癌细胞对顺铂敏感。
Cancer Res. 2019 Jul 1;79(13):3185-3191. doi: 10.1158/0008-5472.CAN-19-0542. Epub 2019 May 6.
10
HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.HOTAIR是治疗顺铂耐药性卵巢癌的一个潜在靶点。
Mol Med Rep. 2015 Aug;12(2):2211-6. doi: 10.3892/mmr.2015.3562. Epub 2015 Mar 27.

引用本文的文献

1
Machine learning tools for deciphering the regulatory logic of enhancers in health and disease.用于解读健康与疾病中增强子调控逻辑的机器学习工具
Front Genet. 2025 Aug 13;16:1603687. doi: 10.3389/fgene.2025.1603687. eCollection 2025.
2
G-quadruplex structures regulate long-range transcriptional reprogramming to promote drug resistance in ovarian cancer cells.G-四链体结构调控远距离转录重编程以促进卵巢癌细胞的耐药性。
Genome Biol. 2025 Jul 12;26(1):183. doi: 10.1186/s13059-025-03654-y.
3
Integrated machine learning and single-cell analysis reveal the prognostic and therapeutic potential of SUMOylation-related genes in ovarian cancer.整合机器学习与单细胞分析揭示了SUMO化相关基因在卵巢癌中的预后及治疗潜力。
Front Immunol. 2025 Jun 4;16:1577781. doi: 10.3389/fimmu.2025.1577781. eCollection 2025.
4
A Super-Enhancer-Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration-Resistant Prostate Cancer.去势抵抗性前列腺癌中阿比特龙耐药背后的超级增强子驱动转录调控回路
Adv Sci (Weinh). 2025 Aug;12(31):e01284. doi: 10.1002/advs.202501284. Epub 2025 Jun 5.
5
Identification of FLYWCH1 as a regulator of platinum-resistance in epithelial ovarian cancer.鉴定FLYWCH1为上皮性卵巢癌铂耐药的调节因子。
NAR Cancer. 2025 Apr 4;7(2):zcaf012. doi: 10.1093/narcan/zcaf012. eCollection 2025 Jun.
6
High PRMT5 levels, maintained by KEAP1 inhibition, drive chemoresistance in high-grade serous ovarian cancer.由KEAP1抑制维持的高PRMT5水平驱动高级别浆液性卵巢癌的化疗耐药性。
J Clin Invest. 2025 Mar 17;135(6):e184283. doi: 10.1172/JCI184283.
7
Chromatin Organization Governs Transcriptional Response and Plasticity of Cancer Stem Cells.染色质组织调控癌症干细胞的转录反应和可塑性。
Adv Sci (Weinh). 2025 May;12(17):e2407426. doi: 10.1002/advs.202407426. Epub 2025 Mar 7.
8
Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies.增强子重编程:在癌症中的关键作用及有前景的治疗策略
Cell Death Discov. 2025 Mar 3;11(1):84. doi: 10.1038/s41420-025-02366-3.
9
HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond.组蛋白去乙酰化酶驱动的抗癌耐药机制:表观遗传学及其他。
Cancer Drug Resist. 2024 Nov 20;7:46. doi: 10.20517/cdr.2024.103. eCollection 2024.
10
Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer.靶向线粒体:治疗铂耐药性卵巢癌的新方法。
J Transl Med. 2024 Oct 25;22(1):968. doi: 10.1186/s12967-024-05770-y.

本文引用的文献

1
SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.SOX2 和 SOX9 是转移性高级别浆液性癌中临床侵袭性疾病的标志物。
Gynecol Oncol. 2019 Jun;153(3):651-660. doi: 10.1016/j.ygyno.2019.03.099. Epub 2019 Mar 21.
2
Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer.作为克服黏液性卵巢癌化疗耐药性治疗靶点的潜在信号通路。
Biomed Rep. 2018 Mar;8(3):215-223. doi: 10.3892/br.2018.1045. Epub 2018 Jan 17.
3
Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma.抑癌基因是恶性胸膜间皮瘤潜在的基于血浆的表观遗传生物标志物。
Dis Markers. 2017;2017:2536187. doi: 10.1155/2017/2536187. Epub 2017 Dec 13.
4
Upregulated SOX9 expression indicates worse prognosis in solid tumors: a systematic review and meta-analysis.SOX9表达上调提示实体瘤预后较差:一项系统评价与Meta分析
Oncotarget. 2017 Nov 6;8(68):113163-113173. doi: 10.18632/oncotarget.22635. eCollection 2017 Dec 22.
5
Targeted therapy of ovarian cancer including immune check point inhibitor.卵巢癌的靶向治疗,包括免疫检查点抑制剂。
Korean J Intern Med. 2017 Sep;32(5):798-804. doi: 10.3904/kjim.2017.008. Epub 2017 Aug 22.
6
Endoplasmic reticulum stress-induced degradation of DNAJB12 stimulates BOK accumulation and primes cancer cells for apoptosis.内质网应激诱导的DNAJB12降解刺激BOK积累并使癌细胞对凋亡敏感。
J Biol Chem. 2017 Jul 14;292(28):11792-11803. doi: 10.1074/jbc.M117.785113. Epub 2017 May 23.
7
Wnt5a Signaling in Normal and Cancer Stem Cells.正常干细胞与癌症干细胞中的Wnt5a信号传导
Stem Cells Int. 2017;2017:5295286. doi: 10.1155/2017/5295286. Epub 2017 Apr 12.
8
Epidemiology of ovarian cancer: a review.卵巢癌流行病学综述
Cancer Biol Med. 2017 Feb;14(1):9-32. doi: 10.20892/j.issn.2095-3941.2016.0084.
9
The cancer epigenome: Concepts, challenges, and therapeutic opportunities.癌症表观基因组:概念、挑战与治疗机遇。
Science. 2017 Mar 17;355(6330):1147-1152. doi: 10.1126/science.aam7304. Epub 2017 Mar 16.
10
Role of Wnt/β-catenin, Wnt/c-Jun N-terminal kinase and Wnt/Ca pathways in cisplatin-induced chemoresistance in ovarian cancer.Wnt/β-连环蛋白、Wnt/c-Jun氨基末端激酶和Wnt/Ca信号通路在顺铂诱导的卵巢癌化疗耐药中的作用
Exp Ther Med. 2016 Dec;12(6):3851-3858. doi: 10.3892/etm.2016.3885. Epub 2016 Nov 8.